Episode 152: Alison Buttenheim on Europe's vaccine scare, Lilly's Alzheimer's data, & a PR plea
First we unpack the crisis of confidence facing AstraZeneca's Covid-19 vaccine in Europe with Alison Buttenheim, a University Pennsylvania professor who studies vaccine acceptance. Then, we explain th...
18 Mars 202129min
Episode 151: Natasha Loder on Covid vaccines, the demise of Watson Health, and a 'synbio' explainer
We're joined by Natasha Loder, the health policy editor at The Economist — and a London resident — to get her home-country perspective on the U.K.'s Covid vaccine development efforts. Next, we'll talk...
11 Mars 202129min
Episode 150: Ashish Jha on Covid-19 optimism, plus pharma cooperation, & the next pandemic phase
We discuss Merck's decision to help Johnson & Johnson manufacture vaccine doses and whether it'll be a turning point for the drug industry or a relic of Covid-19 history. Then, as we near the one-year...
4 Mars 202131min
Episode 149: Nancy Goodman on Covid vaccines for kids, & Greg Zuckerman on Novavax's remarkable rise
First, pediatric cancer advocate Nancy Goodman joins us to discuss why she believes Covid-19 vaccine trials need to be sped up for teens and children. Then, Wall Street Journal reporter Greg Zuckerman...
25 Feb 202131min
Episode 148: Akshay Sharma on gene therapy's setback, biotech's brashest VCs, & the FDA's future
We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we break down a significant setback for Bluebird Bio’s gene therapy program with some help from Akshay Shar...
18 Feb 202135min
Episode 147: David Fajgenbaum on Covid-19 drugs, the state of the pandemic, & meme biotech stocks
When will we have enough vaccine doses? How many effective Covid-19 drugs are just waiting to be found? And what do Redditors think about biotech? We discuss all that and more this week on “The Readou...
11 Feb 202135min
Episode 146: Paul Offit on vaccine data, 23andMe is going public, & Merck's CEO is retiring
We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we recap a busy week of news, featuring 23andMe's move to go public through a blank-check company, Merck CE...
4 Feb 202134min
Episode 145: Kevin Davies on the CRISPR boom, & Megan Ranney on scientific misinformation
First, we discuss the implications of Johnson & Johnson’s any-day-now data on a one-shot vaccine for Covid-19. Then, Kevin Davies, executive editor of the CRISPR Journal, joins us to talk about the st...
28 Jan 202134min
